On June 11, Pfizer rose 3.03% in regular trading, trading at $26.395/share, with trading value of $2.88 billion. The move was driven by RBC Capital Markets upgrading Pfizer from Underperform to Sector Perform while maintaining a $25 price target.

RBC noted that Pfizer's risk-reward profile has become more balanced following recent share price weakness, with valuations now closer to long-term averages and reduced downside concerns. The brokerage highlighted Pfizer's approximately 7% dividend yield as a key support factor, suggesting it may provide a floor for the stock as income-focused investors step in. Additionally, RBC pointed to two late-stage pipeline catalysts — sigvotatug vedotin in non-squamous non-small cell lung cancer with roughly $1.2 billion peak sales potential, and mevro in metastatic castration-resistant prostate cancer — both carrying approximately 60% probability of success, which could boost market expectations ahead of upcoming data readouts.

According to FactSet, analysts assign Pfizer an average overweight rating with a mean price target of $28.92.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)